Corporate Ownership Update: Boston Scientific Corporation
Boston Scientific Corporation (NYSE: BSX) filed a Form 4 with the Securities and Exchange Commission on 6 November 2026. The filing, submitted by Michael F. Mahoney—chairman, president, and chief executive officer—details recent changes to his personal ownership of the company’s common stock.
Transaction Summary
| Trust / Plan | Description | Shares Transferred | Resulting Holdings |
|---|---|---|---|
| Michael F. Mahoney Term Irrevocable Trust (2025) | Trust administered by an independent trustee | Substantial number of shares (exact count not disclosed) | Direct ownership via the trust |
| Michael F. Mahoney 2‑Year Qualified Annuity Trust (2024) | Trust administered by an independent trustee | Substantial number of shares | Direct ownership via the trust |
| Personal 401(k) Retirement Savings Plan | Employee retirement vehicle | Smaller but significant balance | Indirect holding through the 401(k) plan |
After the transfers, Mr. Mahoney’s total ownership of Boston Scientific’s common stock amounts to approximately 1.6 million shares. This figure includes the shares held directly by the two trusts and the shares held indirectly through his 401(k) plan.
Context and Implications
- Ownership Concentration: The increased holdings consolidate Mr. Mahoney’s position as a major shareholder, reinforcing his influence over corporate strategy and governance.
- Governance Transparency: Filing the Form 4 provides market participants with timely disclosure of insider transactions, in compliance with SEC Regulation Fair Disclosure.
- No Additional Corporate Actions: The filing notes that no other material corporate events, such as mergers, acquisitions, or regulatory filings, were reported at the time of submission.
Industry Classification
Boston Scientific remains classified as a manufacturer of surgical and medical instruments and apparatus. This classification underscores the company’s focus on device development, regulatory approval pathways, and market positioning within the medical devices sector.
Conclusion
The recent insider transaction reflects routine corporate governance practices, with Mr. Mahoney’s expanded stake aligning with his executive responsibilities. The disclosure maintains transparency for investors and regulators, ensuring that changes in insider ownership are promptly communicated in accordance with SEC requirements.
